Advanced Spine and Pain Center, San Antonio, TX.
Pain Physician. 2024 Sep;27(7):E725-E730.
Peripheral neuropathy is estimated to be prevalent in up to 12% of the population, increasing to 30% in older demographics. This makes peripheral neuropathy one of the most common neurological diseases in the United States.
This retrospective study aims to report on the efficacy and safety of peripheral nerve stimulation (PNS) on the treatment of peripheral neuropathy in a commercial setting.
This was a retrospective study. A chart review was conducted for all eligible study patients.
This study was conducted at the Advanced Spine and Pain Center in San Antonio, a center focused on physical medicine and rehabilitation, pain management and advanced interventional procedures that effectively ease pain.
From September 2018 through July 2022, a total of 63 consecutive patients with peripheral neuropathy who presented with chronic pain symptoms originating from the shoulder, hip, knee, ankle, and groin were trialed in this study. All patients were required to be at least 18 years old. These patients underwent PNS therapy via implantation of the Freedom® PNS System (Curonix LLC) in order to treat their chronic pain related to or due to peripheral neuropathy from various peripheral nerve origins.
The mean Numeric Rating Scale (NRS-11) score of 63 patients at baseline was 7.24 (SD, 1.80). At 2-3 weeks postimplantation, the mean NRS-11 score decreased to 3.43 (SD, 2.38). A total of 53 out of the 63 patients reported a reduction in their NRS-11 score at the 2-3 week follow-up. A total of 24 patients completed a long-term follow-up. The mean follow-up time was 763.13 days (SD, 428.42); all patients had their PNS system permanently implanted for at least 8 months (range, 255-1,592 days).
This was a retrospective study investigating the efficacy and safety of the Freedom® PNS System in patients with peripheral neuropathy. We were limited to the data available in the patient charts.
PNS effectively treats chronic pain due to peripheral neuropathy for patients who have failed other conservative treatments.
周围神经病变的患病率估计高达 12%，在老年人群中则增至 30%。这使得周围神经病变成为美国最常见的神经疾病之一。
本回顾性研究旨在报告在商业环境中使用周围神经刺激（PNS）治疗周围神经病变的疗效和安全性。
这是一项回顾性研究。对所有符合条件的研究患者进行了图表审查。
本研究在圣安东尼奥的高级脊柱和疼痛中心进行，该中心专注于物理医学和康复、疼痛管理以及有效的缓解疼痛的先进介入程序。
2018 年 9 月至 2022 年 7 月，共有 63 名患有周围神经病的连续患者接受了这项研究，这些患者表现出源于肩部、臀部、膝盖、脚踝和腹股沟的慢性疼痛症状。所有患者必须年满 18 岁。这些患者通过植入 Freedom® PNS 系统（Curonix LLC）接受 PNS 治疗，以治疗各种周围神经起源的与周围神经病变相关或由其引起的慢性疼痛。
63 名患者的基线 Numeric Rating Scale（NRS-11）平均得分为 7.24（SD，1.80）。植入后 2-3 周，NRS-11 平均得分降至 3.43（SD，2.38）。在 2-3 周的随访中，共有 53 名患者报告 NRS-11 评分降低。共有 24 名患者完成了长期随访。平均随访时间为 763.13 天（SD，428.42）；所有患者的 PNS 系统均永久性植入至少 8 个月（范围 255-1592 天）。
这是一项回顾性研究，调查了 Freedom® PNS 系统在患有周围神经病的患者中的疗效和安全性。我们仅限于患者图表中可用的数据。
对于其他保守治疗失败的患者，PNS 可有效治疗由周围神经病变引起的慢性疼痛。
